Frequent expression of PD‐L1 on circulating breast cancer cells

[1]  A. Ribas,et al.  The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? , 2015, Current opinion in immunology.

[2]  K. Mills,et al.  Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines , 2014, Oncogene.

[3]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[4]  K. Tarte,et al.  High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial , 2014, Leukemia.

[5]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[6]  Y. Kluger,et al.  PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases , 2014, Journal of Cancer.

[7]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.

[8]  Helen M. Moore,et al.  Biospecimen Reporting for Improved Study Quality (BRISQ) , 2013, Transfusion.

[9]  Yibin Kang,et al.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients. , 2013, Cancer cell.

[10]  T. Fehm,et al.  Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials , 2012, Cancer and Metastasis Reviews.

[11]  F. Hodi,et al.  Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.

[12]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[13]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[14]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[15]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[16]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[17]  C. Sotiriou,et al.  HER2-Positive Circulating Tumor Cells in Breast Cancer , 2011, PloS one.

[18]  P. Goss,et al.  Does tumour dormancy offer a therapeutic target? , 2010, Nature Reviews Cancer.

[19]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[20]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[21]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[22]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[23]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[24]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[25]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[26]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[27]  R. Faye,et al.  Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Atkins,et al.  Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. , 2015, International immunology.